|
|
Article: GSK Pays Affiris $28M Up Front in Alzheimer's Vaccine Deal.
- Article from:
- BIOWORLD Today
- Article date:
- October 27, 2008
- Author:
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Catherine Hollingsworth, Staff Writer
GlaxoSmithKline Biologicals SA, of Rixensart, Belgium, and Affiris GmbH entered a collaboration agreement granting GSK exclusive rights to Affiris's Alzheimer's disease vaccine programs targeting the beta-amyloid pathway.
Under the terms, Vienna, Austria-based Affiris will receive an up-front payment of [euro]22.5 million (US$28.5 million) and could be eligible for future milestone payments and royalties. The total potential value of the agreement could reach [euro]430 million in the event of full commercial success of the candidate vaccines.
As part of the deal, GSK is acquiring exclusive rights to ...